TCR and Antigen pipelines to create multiple novel cancer treatmentsOur pipelines
Anocca has created an industrialised cell biology platform to address the fundamental problems that currently limit the potential of next-generation immunotherapies that precisely manipulate the adaptive immune system.
The current central limitation to the widespread application of immunotherapies that harness the adaptive immune system is a paucity of knowledge around HLA-presented disease antigens, and TCRs that target these antigens. The diversity of HLAs between individuals means that there are no universal approaches to target specific disease states.
Though the HLA repertoire of each individual is essentially unique, certain versions of HLA genes are common between individuals within related populations. Anocca conducts systematic disease antigen discovery programs for sets of HLA genes commonly represented in major European and Asian populations to identify ‘shared’ antigens that can be target for treatment in defined segments of the patient population.
Anocca’s focus is to expand access to TCR-modified T-cell therapies for oncology through identification of antigens in a range of HLA genes; beyond the handful of the most common genes that are currently investigated. In this setting, there is a key interplay between Anocca’s antigen platform and our TCR technologies. Identified and characterised disease antigens are submitted to the TCR platform for isolation and characterisation of TCRs that may be deployed directly for TCR-modified T-cell therapies.
In addition to the shared antigen approach for treatment of segmented patient populations, Anocca’s technology is designed for deployment on an entirely individualised basis. In this case, for example, the tumour of an individual patient can be analysed to determine ‘neoantigens’ that arise from mutations in the genome of cancer cells. The functionally validated patient-specific antigens can be deployed as individualised vaccines for cancer therapy, or submitted to rapid generation of TCRs for TCR-modified T-cell therapy on an entirely individualised basis.
Cell-based discovery of tumour and viral antigens
Anocca deploys the antigen technologies to discover and validate new cancer antigens, down to the level of individual mutations in specific individual tumours. Our discovery is focused on several target classes including shared tumour antigens, cancer driver mutations and viral proteins. This work is conducted on a library of HLA genes that address a majority of the world-wide population. Anocca is also deploying a technology pipeline to functionally validate neoantigens in tumours that are identified by next generation sequencing on an individualised basis. These pipelines aim to radically expand the access to transformative next-generation of immunotherapies, which include TCR-modified T-cell therapies, but also advanced vaccination approaches.
Robust pipeline of diverse TCRs for deployment in oncology
Anocca has established a pipeline of TCRs against multiple target types, including targets that are shared amongst tumours, against specific genetic mutations that drive cancer, and against viruses that cause cancer. Our pipeline addresses a range of HLA restrictions, expanding the range and quality of available TCRs for both first-in-class and best-in-class approaches, expanding the reach of TCR-modified T-cell therapies. Anocca is also deploying our technology to systematically isolate TCRs for neoantigens identified from tumours on an entirely individualised basis.
Moving beyond oncology
Anocca’s platform has been designed to be re-usable for indications beyond oncology, and in distinct biopharmaceutical applications. In particular, the platform can be deployed in design and deployment of advanced vaccination approaches for personalised tumour vaccines, for prophylactic vaccines for a wide range of pathogens, and for tolerisation of autoimmunity. Anocca has active research programs to deliver novel approaches in these areas, in addition to sophisticated immunosurveillance toolsets for patient management and stratification.